Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK
- Resource Type
- Authors
- Georgia Hollier-Hann; Alistair Curry; Ian Keyzor; Ron Akehurst; Brendan Davies; Kateryna Onishchenko; Fayyaz Ahmed
- Source
- Journal of Medical Economics. 23:113-123
- Subject
- medicine.medical_specialty
Cost effectiveness
Cost-Benefit Analysis
Migraine Disorders
Nice
03 medical and health sciences
0302 clinical medicine
Chronic Migraine
Humans
Medicine
Botulinum Toxins, Type A
Onabotulinumtoxin a
computer.programming_language
business.industry
030503 health policy & services
Health Policy
Cost-effectiveness analysis
United Kingdom
Models, Economic
030220 oncology & carcinogenesis
Chronic Disease
Economic evaluation
Physical therapy
Quality-Adjusted Life Years
0305 other medical science
business
computer
- Language
- ISSN
- 1941-837X
1369-6998
Aims: OnabotulinumtoxinA is recommended by NICE for the treatment of chronic migraine. This economic evaluation provides updated estimates of the cost-effectiveness of onabotulinumtoxinA for chroni...